Annual Cash & Cash Equivalents
$4.77 M
+$1.62 M+51.56%
December 31, 2023
Summary
- As of February 8, 2025, LPCN annual cash & cash equivalents is $4.77 million, with the most recent change of +$1.62 million (+51.56%) on December 31, 2023.
- During the last 3 years, LPCN annual cash & cash equivalents has fallen by -$14.45 million (-75.17%).
- LPCN annual cash & cash equivalents is now -89.46% below its all-time high of $45.26 million, reached on December 31, 2013.
Performance
LPCN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.74 M
-$1.81 M-32.60%
September 30, 2024
Summary
- As of February 8, 2025, LPCN quarterly cash and cash equivalents is $3.74 million, with the most recent change of -$1.81 million (-32.60%) on September 30, 2024.
- Over the past year, LPCN quarterly cash and cash equivalents has dropped by -$1.03 million (-21.56%).
- LPCN quarterly cash and cash equivalents is now -91.73% below its all-time high of $45.26 million, reached on December 31, 2013.
Performance
LPCN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
LPCN Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +51.6% | -21.6% |
| 3 y3 years | -75.2% | -25.4% |
| 5 y5 years | -40.9% | -25.4% |
LPCN Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +61.7% | -34.7% | +56.1% |
| 5 y | 5-year | -75.2% | +61.7% | -80.5% | +56.1% |
| alltime | all time | -89.5% | >+9999.0% | -91.7% | -100.0% |
Lipocine Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $3.74 M(-32.6%) |
| Jun 2024 | - | $5.55 M(+80.2%) |
| Mar 2024 | - | $3.08 M(-35.4%) |
| Dec 2023 | $4.77 M(+51.6%) | $4.77 M(+17.2%) |
| Sep 2023 | - | $4.07 M(-18.8%) |
| Jun 2023 | - | $5.01 M(+5.1%) |
| Mar 2023 | - | $4.77 M(+51.5%) |
| Dec 2022 | $3.15 M(+6.7%) | $3.15 M(+31.4%) |
| Sep 2022 | - | $2.40 M(-51.9%) |
| Jun 2022 | - | $4.98 M(-13.1%) |
| Mar 2022 | - | $5.73 M(+94.3%) |
| Dec 2021 | $2.95 M(-84.6%) | $2.95 M(-34.7%) |
| Sep 2021 | - | $4.52 M(-58.8%) |
| Jun 2021 | - | $10.97 M(-29.7%) |
| Mar 2021 | - | $15.60 M(-18.8%) |
| Dec 2020 | $19.22 M(+97.5%) | $19.22 M(+48.5%) |
| Sep 2020 | - | $12.94 M(-6.5%) |
| Jun 2020 | - | $13.84 M(-8.6%) |
| Mar 2020 | - | $15.13 M(+55.6%) |
| Dec 2019 | $9.73 M(+20.4%) | $9.73 M(+46.0%) |
| Sep 2019 | - | $6.66 M(+81.9%) |
| Jun 2019 | - | $3.66 M(-55.4%) |
| Mar 2019 | - | $8.22 M(+1.8%) |
| Dec 2018 | $8.08 M | $8.08 M(+68.2%) |
| Sep 2018 | - | $4.80 M(+199.8%) |
| Jun 2018 | - | $1.60 M(-81.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $8.56 M(+166.6%) |
| Dec 2017 | $3.21 M(-42.3%) | $3.21 M(-65.4%) |
| Sep 2017 | - | $9.27 M(-44.3%) |
| Jun 2017 | - | $16.63 M(+139.8%) |
| Mar 2017 | - | $6.94 M(+24.7%) |
| Dec 2016 | $5.56 M(-72.2%) | $5.56 M(+18.1%) |
| Sep 2016 | - | $4.71 M(-62.0%) |
| Jun 2016 | - | $12.37 M(-12.3%) |
| Mar 2016 | - | $14.11 M(-29.5%) |
| Dec 2015 | $20.01 M(-27.7%) | $20.01 M(-16.4%) |
| Sep 2015 | - | $23.93 M(-37.5%) |
| Jun 2015 | - | $38.30 M(+54.6%) |
| Mar 2015 | - | $24.76 M(-10.5%) |
| Dec 2014 | $27.67 M(-38.9%) | $27.67 M(-12.6%) |
| Sep 2014 | - | $31.67 M(-7.3%) |
| Jun 2014 | - | $34.16 M(-18.2%) |
| Mar 2014 | - | $41.77 M(-7.7%) |
| Dec 2013 | $45.26 M(>+9900.0%) | $45.26 M(+22.9%) |
| Sep 2013 | - | $36.84 M(>+9900.0%) |
| Jun 2013 | - | $0.00(-100.0%) |
| Mar 2013 | - | $500.00(-16.7%) |
| Dec 2012 | $600.00(-97.4%) | $600.00(0.0%) |
| Sep 2012 | - | $600.00(-82.4%) |
| Jun 2012 | - | $3400.00(-81.0%) |
| Mar 2012 | - | $17.90 K |
| Dec 2011 | $22.90 K | - |
FAQ
- What is Lipocine annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Lipocine?
- What is Lipocine annual cash & cash equivalents year-on-year change?
- What is Lipocine quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Lipocine?
- What is Lipocine quarterly cash and cash equivalents year-on-year change?
What is Lipocine annual cash & cash equivalents?
The current annual cash & cash equivalents of LPCN is $4.77 M
What is the all time high annual cash & cash equivalents for Lipocine?
Lipocine all-time high annual cash & cash equivalents is $45.26 M
What is Lipocine annual cash & cash equivalents year-on-year change?
Over the past year, LPCN annual cash & cash equivalents has changed by +$1.62 M (+51.56%)
What is Lipocine quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LPCN is $3.74 M
What is the all time high quarterly cash and cash equivalents for Lipocine?
Lipocine all-time high quarterly cash and cash equivalents is $45.26 M
What is Lipocine quarterly cash and cash equivalents year-on-year change?
Over the past year, LPCN quarterly cash and cash equivalents has changed by -$1.03 M (-21.56%)